Johnson Financial Group Inc. raised its holdings in Gilead Sciences (NASDAQ:GILD) by 12.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 42,495 shares of the biopharmaceutical company’s stock after purchasing an additional 4,634 shares during the period. Johnson Financial Group Inc.’s holdings in Gilead Sciences were worth $3,044,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Welch Investments LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $108,000. Wealthcare Advisory Partners LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $133,000. Horan Capital Advisors LLC. bought a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $144,000. Hanson & Doremus Investment Management lifted its holdings in shares of Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $147,000. 77.91% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ GILD opened at $74.82 on Friday. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54. The company has a market capitalization of $96,158.94, a price-to-earnings ratio of 8.74, a price-to-earnings-growth ratio of -1.70 and a beta of 1.19.
The firm also recently declared a quarterly dividend, which was paid on Thursday, March 29th. Shareholders of record on Friday, March 16th were given a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a yield of 3.05%. The ex-dividend date of this dividend was Thursday, March 15th. Gilead Sciences’s dividend payout ratio is 26.64%.
In other Gilead Sciences news, EVP James R. Meyers sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total value of $8,024,000.00. Following the completion of the transaction, the executive vice president now directly owns 102,715 shares in the company, valued at approximately $8,241,851.60. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 30,000 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $79.00, for a total transaction of $2,370,000.00. Following the completion of the transaction, the executive vice president now owns 57,114 shares of the company’s stock, valued at $4,512,006. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 426,934 shares of company stock valued at $33,847,101. Corporate insiders own 1.30% of the company’s stock.
GILD has been the subject of a number of recent analyst reports. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target for the company. in a report on Wednesday, January 17th. Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a report on Thursday, December 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Maxim Group set a $94.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Monday, December 11th. Finally, Wells Fargo raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $79.02 to $96.00 in a report on Tuesday, January 16th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $88.61.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.